Anavex Life Sciences Corp (AVXL)

[crescentmotor]

...remains a mystery, but most like it is a conceptual marketing ploy.

100% wrong as supported by your 75% odds for European approval. Blarcamesine, a proven effective in mild AD with stellar safety and efficacy results in many patients as demonstrated in the results of its Phase 2b/III clinical trial and further documented in its MAA currently pending before the CHMP in Europe for likely recommendation in twenty days for regulatory approval.